Sangamo Therapeutics announced updated preliminary clinical data from its Phase 1/2 STAAR study for isaralgagene civaparvovec, showing positive results in treating Fabry disease, with 33 patients treated and a mean annualized eGFR slope of 3.061 mL/min/1.73m2/year indicating potential kidney function improvement. The FDA has provided a clear regulatory pathway for Accelerated Approval, with a potential BLA submission expected in the second half of 2025.